As per reports, UnitedHealth Group Incorporated (UNH) and Drugmaker Eli Lilly & Co and have come together to conduct a study of Lilly’s COVID-19 antibody treatment bamlanivimab in patients who are at risk of becoming severely infected such as those over the age of 65 or the ones suffering from other health conditions such as diabetes.
UnitedHealth is inviting its Medicare Advantage program members to volunteer for the study cause. Participants suffering from COVID-19 symptoms and testing positive will be given bamlanivimab by intravenous infusion with the help of a nurse sent to the comfort of their home.
UnitedHealth’s chief scientific officer, Ken Ehlert, informed that the study aims to determine if Lilly’s drug helps to lessen the severity of COVID-19 by treating people as early as possible in the course of illness.
Bamlanivimab belongs to the class of drugs known as monoclonal antibodies, customed to target the coronavirus.
Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. To learn more about (UNH) please visit the Vista Partners Company Dedicated UNH Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.